Justine Ryu, MD
Assistant ProfessorDownloadHi-Res Photo
Cards
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileContact Info
About
Copy Link
Titles
Assistant Professor
Biography
Dr. Ryu is an Assistant Professor of Medicine (Hematology). She completed her fellowship at Beth Israel Deaconess Medical Center (BIDMC) where she also completed her residency and the T32 Blood Coagulation and Vascular Biology Program. She received her medical degree from Boston University School of Medicine.
Dr. Ryu cares for patients as part of the Smilow Classical Hematology Program in Orange, CT. She treats patients with thrombosis, anemia, bleeding and platelet disorders, and other hematological conditions and rare diseases. Her current area of research is focused on whole-genome sequencing in the All of Us Research Program and she has published numerous peer-reviewed manuscripts in journals including Blood Advances, Cell Reports, and Spine. During fellowship, she also completed the Program in Clinical Effectiveness through Harvard T.H. Chan School of Public Health to strengthen quantitative and analytic skills needed for clinical research.
Last Updated on September 27, 2023.
Appointments
Medical Oncology and Hematology
Assistant ProfessorPrimary
Other Departments & Organizations
- Classical Hematology at Smilow Cancer Hospital
- Hematology
- Internal Medicine
- Medical Oncology and Hematology
- Yale Medicine
- Yale New Haven Health System
Education & Training
- Clinical Fellow
- Beth Israel Deaconess Medical Center (2023)
- T32 Postdoctoral Fellow in Hemostasis and Thrombosis
- Beth Israel Deaconess Medical Center (2020)
- Resident
- Boston Medical Center (2019)
- MD
- Boston University School of Medicine
Research
Copy Link
Research at a Glance
Yale Co-Authors
Frequent collaborators of Justine Ryu's published research.
Publications Timeline
A big-picture view of Justine Ryu's research output by year.
Quinton (Ding Quan) Ng, PhD, BSc (Hon)
George Goshua, MD, SM, FACP
Jihoon Kim, PhD
Lucila Ohno-Machado, MD, MBA, PhD
Satoko Ito, MD, PhD
15Publications
109Citations
Publications
2026
Clinically Relevant Bleeding in Individuals With Cancer: Insights From a Nationwide Cohort Study
Lim M, Gangaraju R, Jafari O, Yang Z, Tiong J, Chiang E, Ma S, Jiang J, Ryu J, Lam B, Ranjan M, Li A. Clinically Relevant Bleeding in Individuals With Cancer: Insights From a Nationwide Cohort Study. American Journal Of Hematology 2026 PMID: 42237094, DOI: 10.1002/ajh.70394.Peer-Reviewed Original ResearchConceptsClinically Relevant BleedingVenous thromboembolismRelevant bleedingOverall cohortCumulative incidenceSystemic antineoplastic therapyCancer diagnosisHistory of bleedingPeriod prevalenceHigher comorbidity indexMultivariable adjusted analysesNationwide cohort studyAssociated with mortalityCancer careBaseline anticoagulationMetastatic diseaseSystemic therapyLaboratory featuresAntineoplastic therapyIntracranial hemorrhageAntiplatelet useGastrointestinal bleedingEarly presentationIncident cancerBleedingJAKPOT Prediction Rule for Erythrocytosis: External Validation and Cost‐Effectiveness Analysis
Lam B, Ito S, Ryu J, O'Sullivan K, Potnis K, Lu R, Bidikian A, Ng D, Singh R, Deter A, Carfagnini C, Bechara S, Kandula M, Do N, Fillmore N, Freed J, Patell R, La J, Goshua G. JAKPOT Prediction Rule for Erythrocytosis: External Validation and Cost‐Effectiveness Analysis. American Journal Of Hematology 2026 PMID: 42227164, DOI: 10.1002/ajh.70390.Peer-Reviewed Original ResearchSurvival assessment of warfarin and international normalized ratio exposure in cancer-associated venous thromboembolism: Veterans Affairs healthcare system-based analysis.
Ryu J, La J, Patell R, Li A, Do N, Brophy M, Fillmore N, Zwicker J. Survival assessment of warfarin and international normalized ratio exposure in cancer-associated venous thromboembolism: Veterans Affairs healthcare system-based analysis. Haematologica 2026 PMID: 41924910, DOI: 10.3324/haematol.2025.300306.Peer-Reviewed Original ResearchConceptsLow-molecular-weight heparinDirect oral anticoagulantsPopulation-based cohort studyVenous thromboembolismOverall survivalWarfarin useEfficacy of direct oral anticoagulantsTreatment of cancer-associated thrombosisPopulation-based cohort study of patientsCancer-associated venous thromboembolismLow riskCohort study of patientsNon-warfarin groupVeterans AffairsCancer-associated thrombosisPropensity-matched patientsStudy of patientsLow risk of mortalityRandomized clinical trialsSurvival assessmentRisk of mortalityWarfarin groupMedian survivalOral anticoagulantsSurvival benefitEpidemiology of Cancer‐Associated Venous Thromboembolism Across the United States
Lam B, Ryu J, Jafari O, Kim B, Ma S, Ranjan M, Jiang J, Li A. Epidemiology of Cancer‐Associated Venous Thromboembolism Across the United States. American Journal Of Hematology 2026, 101: 1005-1018. PMID: 41796432, PMCID: PMC13055130, DOI: 10.1002/ajh.70271.Peer-Reviewed Original ResearchCitationsConceptsCancer-associated venous thromboembolismCumulative incidence of venous thromboembolismIncidence of venous thromboembolismYear of cancer diagnosisElectronic health record systemsEpic electronic health record systemCancer diagnosisHealth record systemsCumulative incidenceRisk factorsVenous thromboembolismVenous thromboembolism typeUnited StatesMajor risk factorsDiagnosis dateUS CensusInsurance coverageOccurrence of venous thromboembolismEpidemiological studiesRecording systemCox regressionCollaborative datasetsPatient populationHomogeneous patient populationCancer typesPopulation-scale analysis reveals inherited C1-inhibitor deficiency is a polyphenotypic thrombotic disorder
Espada A, Haj A, Jurgens S, Eswaran H, Björkman L, Ryu J, Chaudhry S, Koyama S, Wang X, Choi S, Sanna-Cherchi S, Banerji A, Rämö J, Ellinor P, Grover S, Bendapudi P. Population-scale analysis reveals inherited C1-inhibitor deficiency is a polyphenotypic thrombotic disorder. Blood Advances 2026, 10: 931-938. PMID: 41026970, PMCID: PMC12905601, DOI: 10.1182/bloodadvances.2025017220.Peer-Reviewed Original ResearchCitationsAltmetricConceptsHAE-C1INHVariant carriersC1INH deficiencyPopulation-scale datasetsThrombosis riskAssociated with hereditary angioedemaThrombotic disordersC1 inhibitorRisk of venous thromboembolismDeleterious variantsGenetic constraintsLifetime attributable riskGermline lossCoding variationThrombosis phenotypePeripheral arterial diseaseNon-cardioembolic ischemic strokeEffect size estimatesHereditary angioedemaNon-carriersAttributable riskC1INH levelsVenous thromboembolismArtery diseaseIndependent cohort
2025
Comparing survival with vitamin K antagonists, low-molecular-weight heparin, and direct oral anticoagulants in patients with cancer—a systematic review and meta-analysis
Xirou V, Patel A, Altamirano M, Singh R, Gusdorf J, Barnum K, McNichol M, Ryu J, Zwicker J, Chiasakul T, Patell R. Comparing survival with vitamin K antagonists, low-molecular-weight heparin, and direct oral anticoagulants in patients with cancer—a systematic review and meta-analysis. Research And Practice In Thrombosis And Haemostasis 2025, 10: 103268. PMID: 41560781, PMCID: PMC12814848, DOI: 10.1016/j.rpth.2025.103268.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsVitamin K antagonistsLow-molecular-weight heparinDirect oral anticoagulantsAssociated with lower mortalityVenous thromboembolismNon-VKAsK antagonistsOral anticoagulantsCancer patientsIndication of venous thromboembolismCancer-associated venous thromboembolismObservational studySystematic reviewMeta-analysisLower mortalityFollow-up periodStandard of careRandomized Controlled TrialsWeb of ScienceSurvival benefitSolid malignanciesFrequent complicationSubgroup analysisRandomized trialsClinical trialsValidation of a Risk Score for Cancer-Associated Thrombosis Using Nationwide EHR Data
Li A, Jafari O, Lam B, Jiang J, Kim B, Ma S, Zhou E, Tiong J, Chiang E, Ryu J, Amos C, La J, Fillmore N. Validation of a Risk Score for Cancer-Associated Thrombosis Using Nationwide EHR Data. JAMA Network Open 2025, 8: e2544428. PMID: 41288979, PMCID: PMC12648341, DOI: 10.1001/jamanetworkopen.2025.44428.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsTrial exclusion criteriaRisk scoreHealth System sitesKhorana scorePrognostic studyVenous thromboembolismIncident venous thromboembolismExclusion criteriaCancer-associated thrombosisHigh riskEHR-dataRisk prediction modelVenous thromboembolism riskFollow-upHealth systemEHR dataEHR databaseContemporary cohortCancer associationVTE diagnosisAnticoagulant prescriptionActive cancerHematologic malignant neoplasmsCohort of patientsRisk groupsCoagulation factor XII haploinsufficiency is protective against venous thromboembolism in a population-scale multidimensional analysis
Haj A, Paul D, Jurgens S, Eswaran H, Weng L, Ryu J, Rodriguez Espada A, Chaudhry S, Feingold L, Burke K, Koyama S, Wang X, Francis J, Choi S, Mackman N, Bergmeier W, Burgin A, Rämö J, Ellinor P, Grover S, Bendapudi P. Coagulation factor XII haploinsufficiency is protective against venous thromboembolism in a population-scale multidimensional analysis. Nature Communications 2025, 16: 8176. PMID: 40890099, PMCID: PMC12402198, DOI: 10.1038/s41467-025-62789-5.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsRisk of bleedingVenous thromboembolismHeterozygous lossHeterozygous carriersVariant carriersFactor XIISplice site variantFactor XII levelsCoagulation factor XIIFactor XII concentrationHeterozygous miceThrombin generationThromboembolismHaploinsufficient stateXII levelsWild-typeIntermediate phenotypesSite variantsBleedingPotential drug targetsHuman dataCoding regionGenetic variationF12 locusDrug targetsDevelopment and validation of venous thromboembolism–bidirectional encoder representations from transformers (VTE-BERT) natural language processing model
Jafari O, Ma S, Lam B, Jiang J, Zhou E, Ranjan M, Ryu J, Bandyo R, Maghsoudi A, Peng B, Amos C, Oluyomi A, Fillmore N, La J, Li A. Development and validation of venous thromboembolism–bidirectional encoder representations from transformers (VTE-BERT) natural language processing model. Journal Of Thrombosis And Haemostasis 2025, 24: 2522-2531. PMID: 40754035, PMCID: PMC12360494, DOI: 10.1016/j.jtha.2025.07.021.Peer-Reviewed Original ResearchCitationsAltmetricConceptsHarris Health SystemIncident VTE eventsHealth systemNatural language processingVTE eventsVeterans Affairs Healthcare SystemNational Veterans Affairs Healthcare SystemManual chart reviewVenous thromboembolismDischarge summariesHealthcare systemHealthcare institutionsPatient levelNLP modelsAcute VTE eventAdvanced cancerClinical notesNatural language processing applicationsEpidemiological studiesNatural language processing modelsChart reviewLongitudinal studyBidirectional Encoder RepresentationsInternal validityLanguage processing modelsPopulation-Scale Studies of Protein S Abnormalities and Thrombosis
Chaudhry S, Haj A, Ryu J, Jurgens S, Espada A, Wang X, Choi S, Sanna-Cherchi S, Grover S, Bauer K, Ellinor P, Bendapudi P. Population-Scale Studies of Protein S Abnormalities and Thrombosis. JAMA: The Journal Of The American Medical Association 2025, 333: 1423-1432. PMID: 40029645, PMCID: PMC11877412, DOI: 10.1001/jama.2025.0155.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsMeSH KeywordsCross-Sectional StudiesExome SequencingFemaleFollow-Up StudiesGenetic VariationHumansIncidenceLogistic ModelsLongitudinal StudiesLoss of Function MutationMaleMiddle AgedMutation, MissenseProtein SProtein S DeficiencyProteomicsRisk FactorsUK BiobankUnited KingdomUnited StatesVenous ThromboembolismConceptsAssociated with venous thromboembolismPeripheral arterial diseasePopulation cohortUS National InstitutesElevated riskLongitudinal population cohortUK Biobank participantsUK Biobank cohortGermline whole-genome sequencingGenetic variantsVariant carrier statusVenous thromboembolismCross-sectional studyGermline genetic variantsUS National Institutes of HealthIndividual-level dataNational Institutes of HealthVenous thromboembolism riskClinical decision-makingBiobank cohortBiobank participantsUK BiobankRisk of venous thromboembolismInstitutes of HealthMain Outcomes
Clinical Care
Copy Link
Overview
Justine Ryu, MD, specializes in treating blood disorders, such as sickle cell anemia, platelet disorders, leukemia, lymphoma, multiple myeloma, atypical hemolytic uremic syndrome (aHUS), and polycythemia.
Dr. Ryu is an assistant professor at Yale School of Medicine.
Clinical Specialties
Hematology
Fact Sheets
Bleeding Disorders
Learn More on Yale MedicineSickle Cell Disease
Learn More on Yale Medicine
Yale Medicine News
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileNews
Copy Link
News
- December 18, 2024
Yale research advances presented at American Society of Hematology annual meeting
- November 26, 2024
Yale Cancer Center to Highlight Breakthroughs in Blood Cancers and Disorders at World’s Largest Hematology Meeting
- November 28, 2023
Yale Cancer Center Experts Present New Research at Hematology Annual Meeting
Get In Touch
Copy Link
Contacts
Email
Appointment Number
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.